Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 8.

Journal Article

Breyer, J., Monga, M., Mayr, R., Otto, W., Burger, M., Eckstein, M., Stoehr, R., Erben, P., Bolenz, C., Eidt, S., Sundaram, R., Baig, M., Galluzzi, A., Wirtz, R., Hartmann, A. and Santiago-Walker, A. (2020). Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC). Ann. Oncol., 31. S. S587 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Groneck, V. and Eidt, S. (2021). A 54-year-old man with odynophagia. Gastroenterologe, 16 (5). S. 387 - 390. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1861-969X

Marme, F., Schneeweiss, A., Aigner, J., Eidt, S., Altevogt, P., Sinn, P. and Wirtz, R. M. (2012). Ki-67 mRNA as a predictor for response to neoadjuvant chemotherapy in primary breast cancer. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Schloesser, H. A., Shimabukuro-Vornhagen, A., Scherwitz, P., Koslowsky, T., Eidt, S., Stippel, D. L. and von Bergwelt-Baildon, M. S. (2014). Characterization of tumor associated b cells in colorectal cancer. Oncol. Res. Treat., 37. S. 45 - 46. BASEL: KARGER. ISSN 2296-5262

Wirtz, R. M., Aigner, J., Marme, F., Eidt, S., Altevogt, P., Sinn, P. and Schneeweiss, A. (2013). High tumor CD68 mRNA content (intratumoral macrophages) predicts response to neoadjuvant chemotherapy. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2012). CXCL13 mRNA predicts Docetaxel benefit in Triple Negative tumors. Cancer Res., 72. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Wirtz, R. M., Leinonen, M., Bono, P., Isola, J., Kellokumpu-Lehtinen, P-L, Kataja, V., Turpeenniemi-Hujanen, T., Jyrkkio, S., Eidt, S., Schmidt, M. and Joensuu, H. (2013). Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

Wirtz, R. M., Scheffen, I., Marme, F., Laible, M., Sclombs, K., Schumacher, C., Schneeweiss, A., Eidt, S. and Sinn, H-P (2017). Predictive value of ultra-high ESR1 mRNA expression in early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445

This list was generated on Sun May 22 08:25:22 2022 CEST.